Hologic, Inc. (HOLX) Director Namal Nawana Buys 6,600 Shares

Hologic, Inc. (NASDAQ:HOLX) Director Namal Nawana purchased 6,600 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded up $0.23 during trading hours on Wednesday, hitting $38.03. The stock had a trading volume of 3,320,590 shares, compared to its average volume of 3,012,295. The stock has a market capitalization of $10,519.17, a P/E ratio of 10.03, a P/E/G ratio of 1.72 and a beta of 0.77. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. Hologic, Inc. has a twelve month low of $35.33 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 earnings per share. research analysts forecast that Hologic, Inc. will post 2.25 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Grove Bank & Trust grew its position in Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares during the period. National Asset Management Inc. purchased a new stake in Hologic during the second quarter valued at about $203,000. NuWave Investment Management LLC purchased a new stake in Hologic during the fourth quarter valued at about $199,000. Advisor Partners LLC purchased a new stake in Hologic during the fourth quarter valued at about $209,000. Finally, Fiduciary Trust Co. purchased a new stake in Hologic during the fourth quarter valued at about $208,000. 93.84% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the company. Canaccord Genuity reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Friday, February 9th. Stifel Nicolaus cut Hologic from a “buy” rating to a “hold” rating and cut their price target for the stock from $45.00 to $42.00 in a report on Friday, February 9th. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $44.00 price target on shares of Hologic in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $48.00.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Director Namal Nawana Buys 6,600 Shares” was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/hologic-inc-holx-director-namal-nawana-buys-6600-shares.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply